Life Sciences Sequencing

Comprehensive solutions for every stage of clinical development
Tempus leverages best-in-class laboratories to provide a variety of next-generation sequencing (NGS) tests and targeted arrays to support testing needs from discovery through to commercialization.

Strategic support for multiple stakeholders and projects

Proven partnership

Tempus xT CDx¹

(FDA authorized)

648 gene panel, tumor/normal matched for solid tumors, and two companion diagnostic (CDx) claims for colorectal cancer (CRC) patients.

• 500x median coverage of tumor samples
• 95% of exons at >150x coverage
• ≥98% of exons at ≥100x coverage
• SNVs, MNVs, insertions/deletions, MSI

Tempus xR IVD²

(FDA authorized)

xR IVD is an NGS-based in vitro diagnostic test for the detection of BRAF and RET rearrangements in FFPE tumor tissue specimens from patients with solid malignant neoplasms.

Tempus xT

648 gene panel for heme and solid tumors.

• ~500x coverage
• SNVs, insertions/deletions, CNVs, fusions for select genes, MSI, TMB

May be ordered as a standalone assay or in combination with xR.

Tempus xR

Whole transcriptome RNA seq panel for solid tumors and hematologic malignancies.

May be ordered as a standalone assay or in combination with xT.

Tempus xF+

523 gene liquid biopsy panel (114 gene enhanced region).

• Clinical sequencing is performed to >5000x and >1500x unique coverage for enhanced and non-enhanced regions, respectively
• SNVs, MNVs, insertions/deletions, CNGs, and fusions for select genes, MSI-H, bTMB
• Measures changes in ctDNA tumor fraction to determine early response to immunotherapy for patients with advanced cancers

Tempus xE

Whole exome, tumor/normal matched and whole transcriptome RNA-seq. Heme and solid tumors.

• DNA: ~500x (650 genes), 250x for rest
• DNA: SNVs, insertions/deletions, CNVs, TMB, MSI
• RNA: ~50 million reads
• RNA: Fusions, expression, altered splicing

Tempus xH

A whole genome sequencing assay for hematologic malignancies that detects a comprehensive range of alterations, including complex structural variants.

• Whole genome sequencing
• SNVs, indels, CNAs, structural variants, virtual karyotyping

Tempus xH+

Powered by GenoPredictaTM

An ultrasensitive whole-genome sequencing (WGS) assay for comprehensive genomic characterization and Measurable Residual Disease (MRD) monitoring in hematologic malignancies.

• MRD-level sensitivity (10⁻⁶) from as few as 50 cells
• The equivalent of three tests in one: Flow cytometry, cytogenetics, and WGS
• Minimally invasive blood-based option

CancerNext® and CancerNext-Expanded®

40 or 77 gene panel, covers genes associated most common hereditary cancer types.

• DNA: ~500x coverage
• DNA: SNVs, insertions/deletions, CNVs, fusions

Tempus xM MRD

Tumor-naïve Minimal Residual Disease Detection. A liquid biopsy test that detects trace amounts of residual ctDNA in patients with stage II-III colorectal cancer.

Tempus xM (NeXT Personal®)

Test by Personalis

Tumor-informed Minimal Residual Disease Detection.³ A whole genome assay that enables detection of ctDNA to monitor residual disease and recurrence.

Tempus IO™ is a comprehensive immunotherapy platform that provides actionable and cutting-edge services for life sciences partners advancing IO therapies, including antibody-drug conjugates (ADCs), TCR therapies, and immune checkpoint inhibitors (ICIs).

Powering clinical development with data and technology

We operate CAP-accredited, CLIA-certified robotic sequencing labs in Chicago, Atlanta, and Raleigh with automated bioinformatics and variant classification reporting. Sequencing is typically completed within a median of 8 days after receiving samples.

1. xT CDx is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes, as well as microsatellite instability (MSI) status, using DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE) tumor tissue specimens, and DNA isolated from matched normal blood or saliva specimens, from previously diagnosed cancer patients with solid malignant neoplasms. The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table in accordance with the approved therapeutic product labeling. Additionally, xT CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product. xT CDx is a single-site assay performed at Tempus AI, Inc., Chicago, IL.For the complete xT CDx label, including companion diagnostic indications and important risk information, please visit tempus.com/xt-cdx-label/.
2. The Tempus xR IVD assay is a qualitative next generation sequencing-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology for detection of rearrangements in two genes using RNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens from patients with solid malignant neoplasms. Information provided by xR IVD is intended to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Results from xR IVD are not intended to be prescriptive or conclusive for labeled use of any specific therapeutic product. For the complete xR IVD label, including intended use, limitations, and important risk information, please visit tempus.com/xr-ivd-label/.
3. Must be bundled with Tempus products or services.

The information on this page is intended for life sciences companies and focuses on research and development applications.